← All trials
NCT04327765
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2020
- Primary completion
- Apr 27, 2020
- Completion date
- Aug 30, 2020
- First posted
- Mar 31, 2020
- Last posted
- Apr 1, 2020
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Alexza Pharmaceuticals, Inc.Lead sponsor
- CelerionCollaborator
- CelerionOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.